Sagimet Biosciences Inc. will present positive 52-week clinical results for denifanstat in moderate to severe acne vulgaris at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The data, generated from the Phase 3 ASC40-304 open-label extension study, will be shared alongside mechanistic findings during the event scheduled for October 8-11. The clinical trial was conducted in China by Sagimet's license partner, Ascletis BioScience Co. Ltd.
Denifanstat is a once-daily oral small molecule fatty acid synthase (FASN) inhibitor. Ascletis holds an exclusive license to develop and commercialize the drug as ASC40 in China, while Sagimet retains rights to the compound in the rest of the world. The company describes denifanstat as targeting dysfunctional metabolic and fibrotic pathways.